Bank Hapoalim BM held its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,800 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Bank Hapoalim BM’s holdings in Bristol-Myers Squibb were worth $100,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Connecticut Wealth Management LLC acquired a new position in Bristol-Myers Squibb in the first quarter valued at about $224,000. Birmingham Capital Management Co. Inc. AL raised its stake in Bristol-Myers Squibb by 4.4% in the first quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after purchasing an additional 3,000 shares in the last quarter. HGK Asset Management Inc. raised its stake in Bristol-Myers Squibb by 20.8% in the first quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after purchasing an additional 53,221 shares in the last quarter. Investment Partners Ltd. OH ADV raised its stake in Bristol-Myers Squibb by 1.4% during the first quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock worth $1,107,000 after acquiring an additional 274 shares in the last quarter. Finally, Goelzer Investment Management Inc. raised its stake in Bristol-Myers Squibb by 85.4% during the first quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock worth $4,100,000 after acquiring an additional 34,735 shares in the last quarter. 69.82% of the stock is owned by institutional investors.

In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.

Several research analysts have recently issued reports on BMY shares. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group restated a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Wednesday, November 1st. SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Finally, Barclays upped their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $64.93.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.97 on Thursday. The company has a market capitalization of $101,508.14, a price-to-earnings ratio of 20.95, a P/E/G ratio of 2.35 and a beta of 1.18. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.77 earnings per share. equities analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Position Maintained by Bank Hapoalim BM” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-position-maintained-by-bank-hapoalim-bm/1749051.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.